Skip to main content

Table 2 Response to maintenance Bevacizumab (mBev) according to activity of Bevacizumab plus Paclitaxel (BT)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

  Response mBev
Activity BT CR PR SD PD
n n(%) n(%) n(%) n(%)
4 CR 4 (100)    
18 PR   12 (66.7)   6 (33.3)
13 SD   1 (7.7) 10 (76.9) 2 (15.4)
  1. mBev, maintenance Bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.